Clinical effectiveness of nirmatrelvir plus ritonavir for patients with COVID-19 and preexisting psychiatric disorders.

Ting-Hui LiuJheng-Yen WuPo-Yu HuangWan-Hsuan HsuMin-Hsiang ChuangYa-Wen TsaiChih-Cheng LaiCharles Lung-Cheng Huang

Published in: Expert review of anti-infective therapy (2024)

NMV-r could mitigate the risk of adverse outcomes in nonhospitalized patients with COVID-19 and preexisting psychiatric disorders. However, only a limited number of patients in this population received adequate treatment, thus emphasizing the importance of promoting its appropriate use.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
randomized controlled trial
chronic kidney disease
systematic review
prognostic factors
patient reported outcomes
patient reported